ClinicalTrials.gg
CompletedNCT02675231monarcHERUpdated Nov 26, 2024Results posted

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

A Phase 2 interventional study of Abemaciclib and Trastuzumab in Hormone Receptor Positive Breast Cancer and HER-2 Positive Breast Cancer, sponsored by Eli Lilly and Company. Completed at 93 sites in 14 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
11th of 55
237 · median 120
Started
2016
with 4 others
Phase 2
27 of 55
12 open now
Registered
7th of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 11th largest by enrollment, is one of 5 that started in 2016, is one of 27 in phase 2, and was the 7th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus physicians choice standard of care chemotherapy in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) locally advanced or metastatic breast cancer after prior exposure to at least two HER2-directed therapies for advanced disease.

03

Conditions studied

  • Hormone Receptor Positive Breast Cancer
  • HER-2 Positive Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of HR+, + breast cancer (BC)
  • unresectable locally advanced recurrent BC or BC
  • adequate tumor tissue available prior to randomization
  • measurable and/or non- according to (RECIST) version 1.1
  • previously received:

    • at least 2 HER2-directed therapies for advanced disease
    • participant must have received trastuzumab emtansine (T-DM1) in any disease setting
  • must have received a taxane in any disease setting
  • may have received any endocrine therapy (excluding fulvestrant)
  • have status due to surgical / natural menopause or chemical ovarian suppression
  • performance status (PS) of 0 to 1 on the scale
  • (LVEF) of 50% or higher at baseline
  • adequate organ function
  • negative serum pregnancy test at baseline (within 14 days prior to randomization) and agree to use medically approved precautions to prevent pregnancy during the study and for 12 weeks following the last dose of abemaciclib if menopause induced by gonadotropin-releasing hormone (GnRH) agonist or radiation
  • discontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture at least 2 weeks prior to randomization and recovered from the acute effects of therapy
  • discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and endocrine therapy), except trastuzumab, for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy
  • are able to swallow capsules

Exclusion criteria

Exclusion Criteria:

  • have visceral crisis
  • known central nervous system (CNS) that are untreated, symptomatic, or require to control symptoms
  • had major surgery within 14 days prior to randomization
  • received prior treatment with any cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor
  • received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of randomization for a nonmyelosuppressive or myelosuppressive agent, respectively
  • have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study
  • history within the last 6 months of symptomatic congestive heart failure, myocardial infarction, or unstable angina
  • history within the last 12 months of any of the following conditions: syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest
  • history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years
  • active bacterial, fungal infection, or detectable viral infection
  • have received any recent (within 28 days prior to randomization)
  • to trastuzumab, murine proteins, fulvestrant, or to any of the
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
237 participants (actual)

Study arms

  • Experimental
    150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant

    150 milligram (mg) abemaciclib given orally every 12 hours (Q12H) of a 21-day cycle; plus 8 milligram per kilogram (mg/kg) trastuzumab intravenous (IV) infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle; plus 500 mg fulvestrant intramuscularly (IM) on day 1, 15 and 29 and then once every 4 weeks thereafter.

    Drug: Abemaciclib · Drug: Trastuzumab · Drug: Fulvestrant

  • Experimental
    150 mg Abemaciclib + 8 mg/kg Trastuzumab

    150 mg abemaciclib given orally Q12H of a 21-day cycle; plus 8 mg/kg trastuzumab IV infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle.

    Drug: Abemaciclib · Drug: Trastuzumab

  • Active comparator
    8 mg/kg Trastuzumab + Standard of Care Chemotherapy

    8 mg/kg trastuzumab IV infusion on Day 1 of a 21-day cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle plus standard of care single agent chemotherapy of physician's choice administered according to product label

    Drug: Trastuzumab · Drug: Standard of Care Single Agent Chemotherapy

Interventions

  • Administered Orally

    Also known as: LY2835219

  • Administered IV

  • Administered IM

  • DrugStandard of Care Single Agent Chemotherapy

    Standard-of-care single-agent chemotherapy of physician's choice administered according to product label

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS time was measured from the date of randomization to the date of investigator-determined objective progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

    Time frame: Baseline to Progressive Disease or Death from Any Cause (Up To 36 Months)

Secondary outcomes

  1. Percentage of Participants With 1 Year Overall Survival (OS)

    OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive. For each treatment arm OS rate at 1 year from the date of randomization was determined using the OS times and was estimated using the Kaplan-Meier method.

    Time frame: Randomization to date of death from any cause assessed at 1 year

  2. Percentage of Participants With 2 Year OS

    OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive. For each treatment arm OS rate at 2 years from the date of randomization was determined using the OS times and was estimated using the Kaplan-Meier method.

    Time frame: Randomization to date of death from any cause assessed at 2 years

  3. Percentage of Participants With 3 Year OS

    OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive. For each treatment arm OS rate at 3 years from the date of randomization was determined using the OS times and was estimated using the Kaplan-Meier method.

    Time frame: Randomization to date of death from any cause assessed at 3 years

  4. Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)

    ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

    Time frame: Baseline to Objective Disease Progression (Up To 36 Months)

  5. Duration of Response (DoR)

    DoR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date.

    Time frame: Date of CR or PR to Date of Objective Disease Progression or Death from Any Cause (Up To 36 Months)

  6. Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)

    Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.

    Time frame: Baseline to Objective Disease Progression (Up To 36 Months)

  7. Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months: Clinical Benefit Rate (CBR)

    Clinical benefit rate defined as percentage of participants with best overall response of CR, PR, or SD with a duration of at least 6 months. CR, PR, or SD were defined using RECIST, v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Percentage of participants = (participants with CR+PR+SD with a duration of at least 6 months /number of participants enrolled) \*100.

    Time frame: Date of CR, PR or SD to 6 Months Post CR, PR or SD (Up To 36 Months)

  8. Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)

    The mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours and typical completion time for this instrument is less than 5 minutes. Mean Interference Score data is reported here. Least square (LS) Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.

    Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 36 Months)

  9. Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)

    EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms. LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.

    Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 36 Months)

  10. Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

    The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. Five dimensions of health status are each assessed with 5 response options and scored as a composite index which were anchored on a scale of 0 to 1 with a higher score representing better health status.LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.

    Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 36 Months)

  11. Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS)

    European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The EQ-5D-5L is assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. A higher score indicates better health state. LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.

    Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 36 Months)

  12. Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib and Its Metabolites (M2 and M20)

    Minimum Steady State Concentration (Cmin,ss) of Abemaciclib and Its Metabolites (M2 and M20) was evaluated. M2 and M20 are 2 major active metabolites of abemaciclib.

    Time frame: Cycle(C)1 Day(D)1,C1D15, C2D1, C2D8, C3D1,C3D15, C4D1, C5D1:pre-dose; C1D1, C2D1, C3D1, C4D1, C5D1:post-dose

07

Results

Posted May 26, 2020

Participant flow

Participant flow — Overall Study
Milestone150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Started797979
Received at least one dose of drug787772
Completed747174
Not completed585
Withdrew: Withdrawal by subject242
Withdrew: Lost to follow-up343

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS time was measured from the date of randomization to the date of investigator-determined objective progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Time frame:
Baseline to Progressive Disease or Death from Any Cause (Up To 36 Months)
Reported as:
Median · Months
Progression Free Survival (PFS)
Months150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Progression Free Survival (PFS)8.3 (5.9 to 12.6)5.7 (4.2 to 7.2)5.7 (5.4 to 6.9)
Statistical analysis
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · Log Rank · p = 0.0506Stratified by number of prior systemic regimens for advanced breast cancer (2 to 3 versus(vs) \>3) and status of disease(measurable vs non-measurable).
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · Log Rank · p = 0.7695Stratified by number of prior systemic regimens for advanced breast cancer (2 to 3 versus(vs) \>3) and status of disease(measurable vs non-measurable).
SecondaryPercentage of Participants With 1 Year Overall Survival (OS)

OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive. For each treatment arm OS rate at 1 year from the date of randomization was determined using the OS times and was estimated using the Kaplan-Meier method.

Time frame:
Randomization to date of death from any cause assessed at 1 year
Reported as:
Number · percentage of participants
Percentage of Participants With 1 Year Overall Survival (OS)
percentage of participants150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Percentage of Participants With 1 Year Overall Survival (OS)77.2 (65.9 to 85.2)77.4 (66.1 to 85.3)69.8 (57.5 to 79.1)
Statistical analysis
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · Log Rank · p = 0.241 · Hazard ratio (hr): 0.68 · 95% CI 0.36 to 1.30Stratified by the number of previous regimens (excluding single-agent endocrine therapy) for advanced breast cancer and the status of disease (measurable vs. non-measurable).
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · Log Rank · p = 0.313 · Hazard ratio (hr): 0.72 · 95% CI 0.38 to 1.36Stratified by the number of previous regimens (excluding single-agent endocrine therapy) for advanced breast cancer and the status of disease (measurable vs. non-measurable).
SecondaryPercentage of Participants With 2 Year OS

OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive. For each treatment arm OS rate at 2 years from the date of randomization was determined using the OS times and was estimated using the Kaplan-Meier method.

Time frame:
Randomization to date of death from any cause assessed at 2 years
Reported as:
Number · percentage of participants
Percentage of Participants With 2 Year OS
percentage of participants150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Percentage of Participants With 2 Year OS55.8 (43.5 to 66.4)55.7 (43.4 to 66.3)43.0 (30.9 to 54.5)
Statistical analysis
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · Log Rank · p = 0.104 · Hazard ratio (hr): 0.67 · 95% CI 0.42 to 1.08Stratified by the number of previous regimens (excluding single-agent endocrine therapy) for advanced breast cancer and the status of disease (measurable vs. non-measurable).
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · Log Rank · p = 0.120 · Hazard ratio (hr): 0.69 · 95% CI 0.43 to 1.10Stratified by the number of previous regimens (excluding single-agent endocrine therapy) for advanced breast cancer and the status of disease (measurable vs. non-measurable).
SecondaryPercentage of Participants With 3 Year OS

OS is defined as the time from the date of randomization until death from any cause. For participants not known to have died by the data-inclusion cutoff date, OS is censored at the last date they were known to be alive. For each treatment arm OS rate at 3 years from the date of randomization was determined using the OS times and was estimated using the Kaplan-Meier method.

Time frame:
Randomization to date of death from any cause assessed at 3 years
Reported as:
Number · percentage of participants
Percentage of Participants With 3 Year OS
percentage of participants150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Percentage of Participants With 3 Year OS46.7 (34.7 to 57.9)40.2 (28.6 to 51.5)29.9 (19.1 to 41.3)
Statistical analysis
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · Log Rank · p = 0.049 · Hazard ratio (hr): 0.65 · 95% CI 0.42 to 1.00Stratified by the number of previous regimens (excluding single-agent endocrine therapy) for advanced breast cancer and the status of disease (measurable vs. non-measurable).
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · Log Rank · p = 0.153 · Hazard ratio (hr): 0.74 · 95% CI 0.48 to 1.12Stratified by the number of previous regimens (excluding single-agent endocrine therapy) for advanced breast cancer and the status of disease (measurable vs. non-measurable).
SecondaryPercentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)

ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

Time frame:
Baseline to Objective Disease Progression (Up To 36 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)
Percentage of participants150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)32.9 (22.5 to 43.3)13.9 (6.3 to 21.6)13.9 (6.3 to 21.6)
SecondaryDuration of Response (DoR)

DoR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date.

Time frame:
Date of CR or PR to Date of Objective Disease Progression or Death from Any Cause (Up To 36 Months)
Reported as:
Median · Months
Duration of Response (DoR)
Months150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Duration of Response (DoR)12.5 (6.5 to 23.5)9.5 (2.8 to 22.7)NA (4.1 to NA)
SecondaryPercentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)

Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.

Time frame:
Baseline to Objective Disease Progression (Up To 36 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)
Percentage of participants150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)78.5 (69.4 to 87.5)74.7 (65.1 to 84.3)67.1 (56.7 to 77.5)
SecondaryPercentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months: Clinical Benefit Rate (CBR)

Clinical benefit rate defined as percentage of participants with best overall response of CR, PR, or SD with a duration of at least 6 months. CR, PR, or SD were defined using RECIST, v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Percentage of participants = (participants with CR+PR+SD with a duration of at least 6 months /number of participants enrolled) \*100.

Time frame:
Date of CR, PR or SD to 6 Months Post CR, PR or SD (Up To 36 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months: Clinical Benefit Rate (CBR)
Percentage of participants150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months: Clinical Benefit Rate (CBR)58.2 (47.4 to 69.1)45.6 (34.6 to 56.6)38.0 (27.3 to 48.7)
SecondaryChange From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)

The mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours and typical completion time for this instrument is less than 5 minutes. Mean Interference Score data is reported here. Least square (LS) Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.

Time frame:
Baseline, 30 Days After Treatment Discontinuation (Up To 36 Months)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)
units on a scale150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)0 ± 0.180.20 ± 0.180.31 ± 0.19
Statistical analysis
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.232 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Mean difference (final values): -0.31
SecondaryChange From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)

EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms. LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.

Time frame:
Baseline, 30 Days After Treatment Discontinuation (Up To 36 Months)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
units on a scale150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Global health status-2.9 ± 1.6-5.9 ± 1.7-1.9 ± 1.8
Functional scale: Physical functioning-1.0 ± 1.6-4.4 ± 1.6-4.5 ± 1.7
Functional scale: Role functioning-2.7 ± 2.2-5.0 ± 2.3-8.2 ± 2.4
Functional scale: Emotional functioning2.4 ± 1.7-0.4 ± 1.81.1 ± 1.8
Functional scale: Cognitive functioning-1.8 ± 1.4-1.1 ± 1.5-1.6 ± 1.6
Functional scale: Social functioning-0.9 ± 1.9-0.9 ± 1.9-2.4 ± 2.0
Symptom scale: Fatigue1.8 ± 1.97.0 ± 2.04.7 ± 2.1
Symptom scale: Nausea and vomiting6.3 ± 1.45.6 ± 1.42.2 ± 1.5
Symptom scale: Pain-2.5 ± 2.13.1 ± 2.14.3 ± 2.2
Symptom scale: Dyspnoea0.7 ± 1.92.9 ± 2.03.7 ± 2.1
Symptom scale: Insomnia-4.4 ± 2.1-1.6 ± 2.22.0 ± 2.3
Symptom scale: Appetite loss6.3 ± 2.35.5 ± 2.42.4 ± 2.5
Symptom scale: Constipation-6.3 ± 1.9-10.5 ± 1.9-3.4 ± 2.0
Symptom scale: Diarrhoea21.5 ± 2.225.3 ± 2.32.2 ± 2.4
Symptom scale: Financial difficulties0.8 ± 2.0-1.9 ± 2.1-3.2 ± 2.2
Statistical analysis
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.689 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Least square (ls) mean difference: -1.0
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.141 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: 3.4
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.095 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: 5.5
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.591 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: 1.3
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.935 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: -0.2
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.578 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: 1.5
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.308 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: -2.9
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.043 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: 4.1
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.026 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: -6.8
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.276 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: -3.1
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.041 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: -6.4
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.262 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: 3.9
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.285 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: -2.9
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = < 0.001 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: 19.3
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.180 (p-values are from Type 3 sums of squares mixed models repeated measures model (MMRM): Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: 4.0
SecondaryChange From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. Five dimensions of health status are each assessed with 5 response options and scored as a composite index which were anchored on a scale of 0 to 1 with a higher score representing better health status.LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.

Time frame:
Baseline, 30 Days After Treatment Discontinuation (Up To 36 Months)
Reported as:
Least squares mean · units on a scale
Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
units on a scale150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score0.01 ± 0.02-0.01 ± 0.02-0.04 ± 0.02
Statistical analysis
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.033 (p-values are from Type 3 sums of squares mixed models repeated measures model: Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: 0.05
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.275 (p-values are from Type 3 sums of squares mixed models repeated measures model: Change from baseline = Treatment + Visit + Treatment\*Visit + Baseline.) · Ls mean difference: 0.03
SecondaryChange From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS)

European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The EQ-5D-5L is assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. A higher score indicates better health state. LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.

Time frame:
Baseline, 30 Days After Treatment Discontinuation (Up To 36 Months)
Reported as:
Least squares mean · millimeter (mm)
Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS)
millimeter (mm)150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS)0.61 ± 1.4-1.64 ± 1.4-0.61 ± 1.5
Statistical analysis
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.546 · Ls mean difference: 1.22
  • 150 mg Abemaciclib + 8 mg/kg Trastuzumab vs 8 mg/kg Trastuzumab + Standard of Care Chemotherapy · MMRM Model · p = 0.620 · Ls mean difference: -1.02
SecondaryPharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib and Its Metabolites (M2 and M20)

Minimum Steady State Concentration (Cmin,ss) of Abemaciclib and Its Metabolites (M2 and M20) was evaluated. M2 and M20 are 2 major active metabolites of abemaciclib.

Time frame:
Cycle(C)1 Day(D)1,C1D15, C2D1, C2D8, C3D1,C3D15, C4D1, C5D1:pre-dose; C1D1, C2D1, C3D1, C4D1, C5D1:post-dose
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib and Its Metabolites (M2 and M20)
nanogram/milliliter (ng/mL)150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab
Abemaciclib134 ± 77155 ± 53
M272.0 ± 12096.5 ± 120
M20136 ± 120181 ± 130

Adverse events

Collected over Baseline till end of follow-up (Up to 6.5 years). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant52/78 (66.7%)24/78 (30.8%)76/78 (97.4%)
150 mg Abemaciclib + 8 mg/kg Trastuzumab55/77 (71.4%)15/77 (19.5%)75/77 (97.4%)
8 mg/kg Trastuzumab + Standard of Care Chemotherapy53/72 (73.6%)14/72 (19.4%)68/72 (94.4%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
Event150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
Febrile neutropeniaBlood and lymphatic system disorders1/780/773/72
SepsisInfections and infestations1/780/773/72
PneumoniaInfections and infestations1/782/772/72
Pleural effusionRespiratory, thoracic and mediastinal disorders0/780/772/72
DiarrhoeaGastrointestinal disorders1/782/770/72
PyrexiaGeneral disorders2/781/770/72
GastroenteritisInfections and infestations2/780/770/72
Acute kidney injuryRenal and urinary disorders2/781/770/72
PneumothoraxRespiratory, thoracic and mediastinal disorders2/780/770/72
LeukopeniaBlood and lymphatic system disorders0/780/771/72
Most frequent other events
Showing 10 of 403
Most frequent other events
Event150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care Chemotherapy
DiarrhoeaGastrointestinal disorders62/7860/7718/72
FatigueGeneral disorders45/7841/7732/72
NeutropeniaBlood and lymphatic system disorders38/7827/7726/72
NauseaGastrointestinal disorders38/7832/7726/72
AnaemiaBlood and lymphatic system disorders30/7820/7716/72
Abdominal painGastrointestinal disorders24/7819/7716/72
ThrombocytopeniaBlood and lymphatic system disorders23/7823/775/72
VomitingGastrointestinal disorders22/7822/7711/72
CoughRespiratory, thoracic and mediastinal disorders21/7812/779/72
Decreased appetiteMetabolism and nutrition disorders19/7816/7713/72

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care ChemotherapyTotal
Mean54.34 ± 10.2554.99 ± 11.0856.77 ± 12.3755.37 ± 11.27
Sex: Female, Male
Sex: Female, Male(Participants)150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care ChemotherapyTotal
Female797979237
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care ChemotherapyTotal
Hispanic or Latino14111237
Not Hispanic or Latino585256166
Unknown or Not Reported7161134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care ChemotherapyTotal
American Indian or Alaska Native0112
Asian15101035
Native Hawaiian or Other Pacific Islander0000
Black or African American3249
White555355163
More than one race0011
Unknown or Not Reported613827
Region of Enrollment
Region of Enrollment(Participants)150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant150 mg Abemaciclib + 8 mg/kg Trastuzumab8 mg/kg Trastuzumab + Standard of Care ChemotherapyTotal
Argentina97319
United States2081745
United Kingdom991028
Spain68317
Greece1124
Canada24410
South Korea1191030
Belgium57719
Brazil3148
Italy2529
Mexico2136
Australia2428
France613827
Germany1247
08

Study locations

93 sites
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • St Jude Medical Center
    Fullerton, California 92835, United States
  • TRIO - Translational Research in Oncology-US, Inc.
    Los Angeles, California 90024, United States
  • USC Norris Cancer Hospital
    Los Angeles, California 90033, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Cancer Care Associates Medical Group
    Redondo Beach, California 90277, United States
  • Central Coast Medical Oncology Corporation
    Santa Monica, California 93454, United States
  • Catholic Health Initiatives (CHI)
    Englewood, Colorado 80112, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33908, United States
  • MD Anderson Cancer Center Orlando
    Orlando, Florida 32806, United States
  • University of Miami Plantation
    Plantation, Florida 33324, United States
  • Florida Cancer Specialists
    Saint Petersburg, Florida 33705, United States
  • Winship Cancer Center Emory University
    Atlanta, Georgia 30322, United States
  • Northside Hospital Cancer Institute
    Atlanta, Georgia 30342, United States
  • Fort Wayne Medical Oncology & Hematology, Inc.
    Fort Wayne, Indiana 46845, United States
  • St Joseph Cancer Center
    Lexington, Kentucky 40509, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Billings Clinic Research Center
    Billings, Montana 59101, United States
  • Brookdale Hospital Medical Center
    Brooklyn, New York 11212, United States
  • North Shore Hematology Oncology Associates
    East Setauket, New York 11733, United States
  • Clinical Research Alliance, Inc
    Lake Success, New York 11042, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of Pennsylvania Hospital
    Philadelphia, Pennsylvania 19104, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Northwest Medical Specialties, PLLC
    Puyallup, Washington 98372, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, 1426, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Caba, 1025, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cordoba, X5000JHGQ, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cordoba, X5000JHQ, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Rioja, 5300, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosario, 2000, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosario, S2000DSV, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Miguel De Tucuman, T4000IAK, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Viedma, 8500, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kurralta Park, 5037, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nedlands, 6009, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Leonards, 2065, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charleroi, 6000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gent, 9000, Belgium
  • Universitair Ziekenhuis Leuven - Gasthuisberg
    Leuven, 3000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Namur, 5000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Porto Alegre, 90610-000, Brazil
  • Instituto COI de Pesquisa Educação e Gestão
    Rio de Janeiro, 22793-080, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sao Paulo, 05651-901, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    São Paulo, 01308-050, Brazil
  • Fundação Antonio Prudente - Hospital do Câncer A.C Camargo
    São Paulo, 01509-900, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Calgary, T2N 4N2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, t2n42n, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Newmarket, L3Y2P9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Ottawa, K1H 8L6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Angers, 49055, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Besancon, 25030, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon, 69373, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montpellier, 34298, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nice, 06189, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75248, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Cloud, 92210, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Villejuif, 94805, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frankfurt am Main, 60431, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Freiburg, 79106, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 22087, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    München, 81675, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Achaia, 26504, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, 115 28, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Genova, 16132, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20132, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sora, 03039, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Daegu, 41404, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Goyang-si, 10408, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seongnam-si, 13620, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 02841, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 03080, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 03722, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 05505, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 06351, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 14050, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico, 06700, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    México City, 03310, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Badajoz, 06080, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08035, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28034, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28040, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41013, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leicester, LE1 5WN, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manchester, M20 4BX, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, Andre F. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020 Jun;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1. Epub 2020 Apr 27. Erratum In: Lancet Oncol. 2021 Mar;22(3):e92. doi: 10.1016/S1470-2045(21)00032-2. Lancet Oncol. 2021 Nov;22(11):e472. doi: 10.1016/S1470-2045(21)00587-8. PubMed 32353342 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Apr 2019, 34 months.

Results were first posted in May 2020, 1 year 1 month after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 34 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2016
First posted
Feb 5, 2016
StartActual
May 23, 2016
Primary completionActual
Apr 8, 2019
CompletionActual
Nov 9, 2023
Results first posted
May 26, 2020
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02675231
Responsible party
Sponsor
First posted
Feb 5, 2016
Start date
May 23, 2016
Primary completion
Apr 8, 2019
Completion
Nov 9, 2023
Results posted
May 26, 2020
Last update
Nov 26, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion